Last updated: February 25, 2026
What is the Drug Associated with NDC 71288-0723?
NDC 71288-0723 corresponds to Efgartigimod alfa-fcz, a monoclonal antibody developed by args for the treatment of adult patients with generalized myasthenia gravis (gMG) with positive anti-acetylcholine receptor (AChR) antibodies.
Market Size and Key Drivers
Target Patient Population
- Prevalence: Approx. 50,000 to 75,000 patients in the U.S. with general myasthenia gravis.
- AChR-positive subset: Around 80% of all myasthenia gravis cases.
- Treatment-eligible population: Estimated 40,000 to 60,000 U.S. patients.
Competitor Landscape
- Existing treatments: Pyridostigmine, corticosteroids, immunosuppressants.
- Emerging treatments: Efgartigimod faces competition from therapies like Ravulizumab and complement inhibitors.
- Market entry impact: Efgartigimod’s approval expands options, potentially capturing 20-40% of therapy-naïve and relapsed patient segments within 3-5 years.
Sales Drivers
- Efficacy: Demonstrates significant improvement in QMG scores.
- Safety profile: Favorable, with fewer immunosuppressive side effects.
- Regulatory approvals: Rapid approvals in key markets boost access and sales.
Pricing Analysis
Current Pricing Trends
- Price per dose: Efgartigimod is administered as an intravenous infusion; estimated at approximately $2,500 to $5,000 per dose, based on comparable monoclonal antibodies.
- Dosing schedule: Weekly doses initially, then biweekly, generally 8-10 doses per treatment cycle.
- Average annual treatment cost: Estimated between $60,000 and $100,000 per patient, depending on dosing and treatment duration.
Market Comparables
| Drug |
Indication |
Approximate Annual Cost |
Key Features |
| Rituximab |
Various autoimmune diseases |
$20,000 – $25,000 |
Off-label use in MG; infusion-based costs |
| Eculizumab |
Generalized MG (complement inhibitor) |
$500,000+ |
High cost, complement pathway targeting |
| Corticosteroids |
MG symptom management |
<$1,000 per year |
Low-cost but with long-term side effects |
Efgartigimod's pricing aims to be competitive compared to high-cost biologics like eculizumab, while offering improved safety and efficacy.
Revenue Projections
Short-term (Year 1-2)
- Sales heavily dependent on initial uptake; rapid approval in the U.S. predicts revenue of approximately $50-100 million.
- Prescriptions may grow 25-50% annually with increased physician adoption.
Medium-term (Year 3-5)
- Market penetration might reach 25-35% of eligible patients.
- Global expansion into Europe and other markets will contribute additional revenues.
- Projected annual sales could reach $300-500 million in the U.S. alone.
Long-term (Year 5+)
- Price adjustments for market competition and inflation are expected.
- Possible expansion to pediatric indications or other autoimmune diseases could increase revenue streams.
Risks to Price and Revenue
- Competitive new entrants.
- Reimbursement challenges.
- Price sensitivity and payer negotiations.
Regulatory and Market Entry Considerations
- FDA Approval: Received in the U.S. in 2021 under accelerated approval, with full approval granted in 2022.
- European Union: Regulatory submission underway, expected approval within 1-2 years.
- Reimbursement Policy: Structured via value-based contracts with payers, emphasizing clinical benefit and safety profile.
Key Takeaways
- Efgartigimod targets a niche but growing market in autoimmune neuromuscular disorders.
- The drug's pricing aligns with current biologic standards, balancing affordability with revenue generation.
- Revenue projections suggest high potential in the first 3-5 years, with sustained growth possible through global expansion and indication evolution.
- Market growth hinges on physician adoption, competition, and payer reimbursement strategies.
FAQs
1. How does Efgartigimod compare price-wise to similar biologics?
It is priced lower than high-cost complement inhibitors like eculizumab but similar to other neuromuscular biologics, aiming for a median annual cost of $60,000-$100,000.
2. What factors influence market penetration?
Efficacy, safety, physician familiarity, insurance reimbursement policies, and the competitive landscape.
3. What are the main risks in price projection?
Entry of biosimilars, payer resistance, and reductions due to market competition.
4. How may international markets impact revenues?
European approval will expand the total addressable market, potentially doubling global sales within 5 years.
5. Which variables most affect future price adjustments?
Market competition, reimbursement negotiations, and evolving indications.
References
[1] FDA. (2022). Efgartigimod approval announcement.
[2] IQVIA. (2022). Biologic drug pricing report.
[3] MarketWatch. (2022). Autoimmune disease therapeutics analysis.
[4] European Medicines Agency. (2023). Efgartigimod submission updates.
